Your session is about to expire
← Back to Search
mRNA Vaccine
mRNA Flu Vaccine for Flu
Verified Trial
Phase 1 & 2
Waitlist Available
Research Sponsored by Sanofi Pasteur, a Sanofi Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
You are at least 18 years old
Answer yes if you have *not* received a Flu Vaccine within the last six (6) months
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1, day 91, day 181 and day 366
Awards & highlights
Study Summary
This trial tests the safety and effectiveness of a new flu vaccine in adults 18+ compared to existing vaccines.
Who is the study for?
This trial is for adults 18 years and older who haven't had a flu shot in the last six months. Participants must be able to attend up to eight study visits over one year.Check my eligibility
What is being tested?
The trial tests a new Quadrivalent Influenza mRNA Vaccine MRT5410 against three other flu vaccines: high dose, standard dose, and recombinant versions. It involves one injection and compares safety and immune response.See study design
What are the potential side effects?
Potential side effects may include pain at the injection site, fatigue, headache, muscle pain, feverish feelings or chills which are common with flu vaccines.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
Have you not received a flu vaccine in the last six months? If yes, then you meet this criterion.
Select...
You are available to come to the study site for up to 8 visits within a year.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1, day 91, day 181 and day 366
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1, day 91, day 181 and day 366
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Individual HAI titer ratio
Individual Hemagglutination inhibition (HAI) titer
Number of participants archiving HAI seroconversion against Antigens
+8 moreSecondary outcome measures
Individual HAI Ab titer ratio
Individual antibodies HAI titer ratio
Individual neutralizing antibodies titer ratio
+3 moreSide effects data
From 2023 Phase 4 trial • 267 Patients • NCT0500704113%
Upper Respiratory Infection
12%
COVID-19 Infection
1%
Chronic Obstructive Pulmonary Disease (COPD) exacerbation
1%
Hepatocellular Carcinoma
1%
Hospitalization for pacemaker due to arrhythmia
1%
Revision of right shoulder rotator cuff surgery
100%
80%
60%
40%
20%
0%
Study treatment Arm
Recombinant Zoster Vaccine (RZV) and Quadrivalent Adjuvanted Influenza Vaccine
Recombinant Zoster Vaccine (RZV) and High-Dose Quadrivalent Influenza Vaccine
Trial Design
6Treatment groups
Experimental Treatment
Active Control
Group I: Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high doseExperimental Treatment1 Intervention
participants will receive a single dose (high) of QIV mRNA vaccine
Group II: Group 2: Quadrivalent Influenza mRNA Vaccine MRT5410 medium doseExperimental Treatment1 Intervention
participants will receive a single dose (medium) of QIV mRNA vaccine
Group III: Group 1: Quadrivalent Influenza mRNA Vaccine MRT5410 low doseExperimental Treatment1 Intervention
participants will receive a single dose (low) of QIV mRNA vaccine
Group IV: Group 6: QIV-HDActive Control1 Intervention
participants will receive a single dose of QIV -HD vaccine
Group V: Group 4: RIV4Active Control1 Intervention
participants will receive a single dose of RIV4 vaccine
Group VI: Group 5: QIV-SDActive Control1 Intervention
participants will receive a single dose of QIV-SD vaccine
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Sanofi Pasteur, a Sanofi CompanyLead Sponsor
408 Previous Clinical Trials
6,093,600 Total Patients Enrolled
Clinical Sciences & OperationsStudy DirectorSanofi
863 Previous Clinical Trials
2,019,486 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am 18 years old or older.Have you not received a flu vaccine in the last six months? If yes, then you meet this criterion.You are available to come to the study site for up to 8 visits within a year.
Research Study Groups:
This trial has the following groups:- Group 1: Group 3: Quadrivalent Influenza mRNA Vaccine MRT5410 high dose
- Group 2: Group 2: Quadrivalent Influenza mRNA Vaccine MRT5410 medium dose
- Group 3: Group 6: QIV-HD
- Group 4: Group 4: RIV4
- Group 5: Group 5: QIV-SD
- Group 6: Group 1: Quadrivalent Influenza mRNA Vaccine MRT5410 low dose
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Flu Shot Patient Testimony for trial: Trial Name: NCT05624606 — Phase 1 & 2
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the current participation rate for this trial?
"Affirmative. Data found on clinicaltrials.gov demonstrates that this medical trial, which launched on November 28th 2022 is currently recruiting patients from 1 medical site with a target of 690 participants."
Answered by AI
Are there currently any open spots for this research trial?
"Clinicaltrials.gov reveals that this medical experiment, initially published on November 28th 2022 and recently amended on the 30th of the same month, is seeking volunteers."
Answered by AI
Who else is applying?
What state do they live in?
Idaho
Florida
Other
Texas
What site did they apply to?
Florida International Research Center-Site Number:8400009
Joint Clinical Trials Huntington Park-Site Number:8400032
Other
Elligo Health Research
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
2
3+
1
0
Why did patients apply to this trial?
Saw study on FB. For the compensate. I’ve never joined a study. I almost died with the flu.
PatientReceived 2+ prior treatments
Interested in clinical trials!
PatientReceived 1 prior treatment
What questions have other patients asked about this trial?
How long are visits? How long are screening visits? If I don't qualify, can you please let me know the reason?
PatientReceived no prior treatments
What do I have to do to complete this trial/survey to get compensated?
PatientReceived 2+ prior treatments
How responsive is this trial?
Average response time
- < 2 Days
Typically responds via
Email
Phone Call
Most responsive sites:
- Elligo Health Research: < 48 hours
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger